Loading
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
NASDAQHealthcareBiotechnology
Latest quote
$3.39
+$0.22 · +6.94%
Previous close
$3.39
+$0.22 · +6.94%
Regular session · ET · Market data may be delayed.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Day range
Current $3.39
52-week range
Current $3.39
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
61
Bullish
Risk
45
Elevated Risk
Momentum
57
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Day range
Current $3.39
52-week range
Current $3.39
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 744.56K USD | 46.18M USD | 54.81M USD | 113.32M USD | 90.62M USD |
| Selling, general, and administrative | 311.9K USD | 37.72M USD | 48.9M USD | 47.93M USD | 35.08M USD |
| Operating expenses | 59.1M USD | 83.89M USD | 103.7M USD | 161.25M USD | 125.7M USD |
| Interest income | 1.4M USD | 3.53M USD | 5.15M USD | 2.66M USD | 1.2M USD |
| Depreciation and amortization | — | — | 103.7M USD | 2K USD | 1.26K USD |
| Operating income | −59.1M USD | −83.89M USD | −103.7M USD | −161.25M USD | −125.7M USD |
| Net income | −57.39M USD | −79.98M USD | −98.79M USD | −157.04M USD | −125.75M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$12.00
253.98% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Sep 30, 2019 | 1:4 | — | — |
Stock split | Aug 12, 2015 | 1:5 | — | — |
Effective Sep 30, 2019
1:4
Effective Aug 12, 2015
1:5
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI13.82M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM7.89M0.01%78.74B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF5.31M0.01%95.4B USD0.05%$235+0.80%
State Street SPDR S&P Pharmaceuticals ETFXPH3.75M0.81%461.57M USD0.35%$64.65+1.60%
iShares Russell 2000 Growth ETFIWO2.73M0.02%13.92B USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO2.37M0.01%18B USD0.06%$112.66+0.50%
AdvisorShares Psychedelics ETFPSIL2.11M4.51%46.85M USD1.84%$21.765+3.69%
Vanguard Health Care ETFVHT1.08M0.00%22B USD0.09%$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAdvisorShares Psychedelics ETFPSILVanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
